Search
Close this search box.

New Underwriting Changes from LGA – Oct. 1, 2020

Effective Thursday, October 1, 2020, Legal & General America has updated their temporary underwriting guidelines in response to COVID-19:

Good Health Statement

  • A Good Health Statement will continue to be required with all new or pending applications unless there is a valid TIAA in place.

Foreign Travel

  • Travel plans to a country with advisory Level 1 or 2 is acceptable.
  • Travel plans to a country with advisory Level 3 or 4 due to COVID-19: if travel will be canceled or delayed until the country is determined to be safe by the CDC and US State department guidelines, LGA will amend the application and proceed with completing the underwriting process.
  • Travel plans to a country with advisory Level 3 or 4 due to civil unrest or terrorism; LGA will postpone the application until after travel takes place.
  • Applicants recently returning from international travel will no longer be postponed. LGA will assess their risk based on answers to our COVID-19 questions during the underwriting process.

COVID-19 Disease Cases Remains Unchanged

  • Postponed for at least 30 days after full recovery. Reconsideration parameters will depend on the severity of the disease and current health status.

Age and Risk Profile Postponement Parameters

  • LGA reserves the option to apply Individual Consideration. Applicants in the age ranges listed below whose assessed risk class exceeds rated table parameters AND the risk profile includes the referenced underlying chronic conditions listed below will generally be postponed for a minimum of 6 months or denied:

Age Ranges and Risk Classes:

  • Ages 55 – 64 and risk profile exceeds Table 6
  • Ages 65 – 70 and risk profile exceeds Table 4
  • Ages 71+ and risk profile exceeds Standard

Underlying Medical Conditions (include but are not limited to):

  • Cardiovascular disease
    • Arrhythmia including Atrial fibrillation, Anticoagulant use
    • Coronary artery disease (CAD)
    • Stroke, TIA
    • Other rateable cardiovascular disease
  • Diabetes
  • Lung Disease
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Bronchitis/pneumonia
    • Other rateable lung disease

LGA’s full announcement